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Abstract
With the existence of biologically distinctive malignant cells originated within the same tumor, intratumor functional
heterogeneity is present in many cancers and is often manifested by the intermingled vascular compartments with distinct
pharmacokinetics. However, intratumor vascular heterogeneity cannot be resolved directly by most in vivo dynamic
imaging. We developed multi-tissue compartment modeling (MTCM), a completely unsupervised method of deconvoluting
dynamic imaging series from heterogeneous tumors that can improve vascular characterization in many biological contexts.
Applying MTCM to dynamic contrast-enhanced magnetic resonance imaging of breast cancers revealed characteristic
intratumor vascular heterogeneity and therapeutic responses that were otherwise undetectable. MTCM is readily applicable
to other dynamic imaging modalities for studying intratumor functional and phenotypic heterogeneity, together with a
variety of foreseeable applications in the clinic.
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Introduction
Intratumor genetic or epigenetic heterogeneity has been found
in many cancers as evidenced by deep sequencing selectively
applied to different parts of the same tumor [1,2]. Consequently,
cancer cells display remarkable phenotypic variability, including
ability to induce angiogenesis, seed metastases, and survive
therapy [3–5]. Advanced solid tumors often contain vascular
compartments with distinct pharmacokinetics, comprising hypoxic
regions and spatially intermingled irregular vasculature that is
leaky and inefficient [6–8]. The complexity of heterogeneity has
clinical implications. A more heterogeneous tumor is more likely to
fail therapy due to increased drug-resistant variants [3,5], and
characteristics of the dominant cell type will not necessarily predict
the behaviors of interest rooted in specific cells [4].
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) provides a noninvasive in vivo method to evaluate
tumor vasculature architectures based on contrast accumulation
and washout [7,9]. While DCE-MRI can potentially depict the
intratumor heterogeneity of vascular permeability [10], the
quantitative application of DCE-MRI has been hindered by its
inability to accurately resolve vascular compartments with distinct
pharmacokinetics due to limited imaging resolution [7,11]. We
emphasize that identification of spatially mixed multiple vascular
cytotypes is principally different from imaging an inhomogen-
eously distributed single vascular cytotype, and it is the former
scenario that presents significant technological challenges to
portraying tumor cytotypes. This indistinction among the contri-
butions of different compartments to the mixed tracer signals can
confound compartment modeling and deep phenotyping for
association studies [4,12,13]. The goal of the present work was
to discern vascular heterogeneity and its changes in tumors using
DCE-MRI and novel mathematical models, for personalized
cancer diagnosis and treatment.
We developed a computational method (multi-tissue compart-
ment modeling - MTCM) for deconvolving intratumor vascular
heterogeneity and identifying pharmacokinetics changes in many
biological contexts [5,14,15]. MTCM works by applying a convex
analysis of mixtures that enables geometrically-principled delinea-
tion of distinct vascular structures from DCE-MRI data (Fig. 1a–
c). A formal mathematical description of the method and its
detailed implementation is available in Methods.
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Results
Overview of MTCM
Tumors to be analyzed by MTCM contain unknown numbers
of distinct vascular compartments. The pixel-wise tracer concen-
tration in a particular vascular compartment is modeled as being
proportional to the local volume transfer constant of the vascular
compartment (Method). Because there are often significant
numbers of partial-volume pixels, MTCM instead estimates
pharmacokinetic parameters (flux rate constants) via the time-
courses of pure-volume pixels (pixels whose signal is highly
enriched in a particular vascular compartment). Convex analysis
of mixtures identifies those pure-volume pixels present at the
vertices of the clustered pixel time series scatter simplex, without
any knowledge of compartment distribution (Method). When the
number of underlying vascular compartments is detected using the
minimum description length (MDL) criterion, MTCM provides a
completely unsupervised approach to characterize intratumor
heterogeneity (Methods and Appendix S1 in File S1).
Modeling the pharmacokinetics of each vascular compartment
using pure-volume pixel time-courses allowed us to estimate
individual compartment flux rate constants (Fig. 1d–e). Non-
negative least-square estimation yielded pixel-wise local volume
transfer constants (Methods and Fig. 1f). Using synthetic and
mouse DCE-MRI experiments, we showed that MTCM can be
used to estimate pharmacokinetic parameters in several vascular
compartments simultaneously and to quantitatively reconstruct
tissue-specific local volume transfer constants (Data S1–S2,
Figs. 2, S1–S2 and Tables S1–S2). Furthermore, MTCM
enabled quantitation of differences in tissue-specific vascular
permeability across time (for example, therapeutic responses in
longitudinal studies; Methods). Thus, the change in values of flux
rate constants in a given vascular compartment could be
determined, despite an expected difference in that vascular
compartment’s relative abundance.
We also analyzed the same realistic synthetic dataset using a
‘‘traditional’’ way of principal component analysis - PCA. By a
comparison of the tracer concentration extracted by PCA
(Fig. 2e) to that estimated by MTCM (Fig. 2d), we can see that
tracer concentration curves estimated by PCA are highly fluctuant
and significant deviated from the ground truth. In fact, similar
unsatisfactory results produced by PCA or classic factor analysis
have been observed in the earlier studies by us and others (Cinotti,
Bazin et al. 1991, Zhou, Huang et al. 1997, Hillman and Moore
2007, Hillman, Amoozegar et al. 2011). We should clarify that
MTCM consists of two major analytic parts: convex analysis of
mixtures (CAM) and compartment modeling (CM), where the
CAM is a critical step that automatically identifies the pure tissue
pixels and their time activity curves, followed by the CM that
estimates the pharmacokinetics parameters without being con-
taminated by the partial-volume effect. In contrast, since PCA
does not enforce the nonnegative constraint for tracer concentra-
tion estimation, a subsequent compartment modeling cannot be
performed to estimate pharmacokinetic parameters.
Intratumor vascular heterogeneity in breast cancer
revealed by MTCM
In keeping with our goal to use MTCM to better uncover
vascular heterogeneity in human tumors, we applied MTCM to
DCE-MRI sequence data obtained from a case of advanced breast
cancer (Fig. 1a). In this breast tumor [7], vascular heterogeneity is
characterized by active angiogenesis in the peripheral ‘‘rim’’ and
Figure 1. The proposed multi-tissue compartment modeling pipeline for uncovering intratumor vascular heterogeneity. (a) On the
DCE-MRI sequence, tumor region is extracted using a digital mask. Then, pixel time-courses are collected and normalized over time. (b) Pixel time-
courses are grouped into clusters with initialization-free multivariate clustering techniques. On the simplex of pixel time-courses, the clusters present
at the vertices are identified by a convex analysis of mixtures. (c) Using pure-volume pixels, multi-compartment modeling is performed to estimate
tissue-specific flux rate constants and volume transfer constants. (d) Scatter simplex of real DCE-MRI data from an advanced breast cancer. (e)
Estimated tissue-specific compartmental time-activity curves: ‘blue’ – plasma input function; ‘red’ – fast flow kinetics; ‘green’ – slow flow kinetics; and
example images of the associated local volume transfer constants. (f) Illustrative microscopic images of normal and abnormal vessel architecture
(McDonald and Choyke, Nat Med 9, 2003).
doi:10.1371/journal.pone.0112143.g001
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concurrent inner-core hypoxia. Upon preliminary analysis using
MDL, we found that a two-tissue compartment model of the fast
and slow tracer clearance rates was sufficient to account for the
variable permeability at the majority of pixels (Methods). Thus, we
used pure-volume pixels associated with these two vascular pools to
estimate tissue-specific flux rate constants and to reconstruct local
volume transfer constant maps (Methods). MTCM reveals two
vascular compartments with distinct flux rate constants (Fig. 1e).
Accordingly, we detected distinct spatial patterns of specific local
volume transfer constant in the two vascular compartments
(Fig. 1f) with a significant fraction of partial volume pixels.
Intratumor vascular heterogeneity identified by MTCM is
consistent with the knowledge obtained from ex vivo microscopic
and molecular studies [7,13]. Defective endothelial barrier
function is one of the better documented abnormalities of tumor
vessels, resulting in functional heterogeneity in vascular perme-
ability to macromolecules [7,11]. As a tumor rapidly outgrows its
blood supply, it requires neovessel maturation, often leaving an
inner core of the tumor with regions where blood flow and oxygen
concentration are significantly lower than in normal tissues [6].
MTCM reconstructed local volume transfer constant maps
correlate well with the differential gene expression known to
regulate angiogenesis [7,13].
Changes in intratumor vascular heterogeneity in
longitudinal studies
We also detected changes in pharmacokinetic patterns among
longitudinal DCE-MRI data from breast cancer acquired before,
during, and after treatment (Fig. 3a), quantified as different flux rate
constants over time (Methods and Table S3). For example, the two
vascular compartment time-activity curves revealed by MTCM in
the baseline data are highly distinct (Fig. 3b). We detected
significantly higher permeability in a fast-flow pool and slightly
lower permeability in a slow-flow pool when compared with the
normal state. In contrast, the interim response (Fig. 3c) exhibits
vascular compartment time-activity curves that are distinct but much
closer to each other, whereas the closing response (Fig. 3d) shows a
significant decrease in permeability of the fast-flow pool. We also
detected different local volume transfer constant maps (Fig. 3b–d)
and changes in the fractions of partial-volume pixels (Table S4).
Comparative studies using standard compartment
modeling
We compared tissue-specific pharmacokinetics detected with
MTCM to the results of a standard compartment analysis of (total)
vascular pool within the region of interest. Total time-activity curves
were indistinct across time (Fig. S2) owing to therapeutic effects in
some parts of the tumor but not in others and large fractions of
partial-volume pixels. In this longitudinal study, we deconvolved
total time-activity curves into two phased therapeutic effects using
MTCM: a transient ‘‘normalization’’ of abnormal yet surviving
tumor vasculature together with the significant and consistent drop
in the relative volume transfer constants [6,16]. In contrast,
standard analysis may not return informative results when both
the flux rate constant and volume transfer constant change
heterogeneously in response to therapy. These examples illustrate
the ability of MTCM to discover intratumor vascular heterogeneity
and to detect changes in each vascular compartment over time.
Finally, we tested the applicability of MTCM to dynamic
fluorescence imaging data acquired on a mouse after bolus injection
of indocyanine green dye by deconvolving biodistribution dynamics
of the major organs [17] (Fig. S3). The dissected tissue
compartments constitute anatomical structures of the mouse that
agree well with a digital anatomical mouse atlas.
Discussion
Several previous studies have discussed the problem of
intratumor vascular heterogeneity in compartment modelling
[7,11,16,18], a major outstanding issue for the characterization
of complex phenotypes and therapeutic responses. Some methods
have addressed the estimation of multi-compartment pharmaco-
kinetics in the presence of varying partial-volume effects, relying
on known regions of pure-volume pixels and number of
compartments [10,13,16,17]. The significant advantage of our
strategy is its ability to detect and quantify intratumor vascular
heterogeneity without any type of external information. The
benefits of such a method include its wide applicability, sensitive
detection of heterogeneity dynamics, and reliance on longitudinal
data from one single subject (Appendix S1 in File S1).
We have identified differential and heterogeneous changes in
tissue-specific vascular pharmacokinetics in tumors during treat-
ment that were undetected using standard analysis, including
tumor islands of persistent enhancement that have escaped the
effects of therapy [18]. These results are particularly intriguing
when considered together with recent imaging studies describing
foci of resistant and more aggressive clones within a tumor [5,13].
While it is not yet possible to assign causality, these in vivo results
allowed us to propose new hypotheses regarding the complex
relationships between intratumor heterogeneity, clonal repopula-
tion, cancer stem-cell, and therapeutic efficacy [1,3,5,10,19].
In metastatic disease, recent studies have revealed the emergence
of treatment-resistant subclones that were present at a minor
frequency in the primary tumour [20]. Thus, modeling cancer
diagnosis and treatment in the future should involve characteriza-
tion of subpopulations within the primary tumour, monitoring of
clonal dynamics during treatment and eradication of treatment-
emergent clones [21]. To prospectively assess intratumor heteroge-
neity, profiling of multiregional tumour samples would be required.
However, it is impractical and potentially risky to take multiple
‘random’ biopsies in every patient, owing to both sampling bias and
the inability to resolve intermingled heterogeneity [22]. MTCM
would not only make longitudinal in vivo surveillance possible but
also enable imaging-informed selective biopsies.
The future challenges of applying MTCM lie in the gap
between research experiments and clinical practice. Unlike high-
quality data in well-designed research studies, clinical data are
usually with limited spatial and/or temporal resolution, accom-
panied by higher noise level (Fig. S4). Lower spatial resolution
results in less pure-volume pixels and thus reduces the accuracy of
MTCM; while limited temporal resolution prevents accurate
differentiation and estimation of pharmacokinetic parameters
associated with distinctive vascular compartments.
So far we have tested MTCM method on DCE-MRI data [7],
dynamic contrast-enhanced optical imaging data [17,23], and
Figure 2. MTCM estimates time-activity curves in multiple vascular compartments simultaneously and quantitatively reconstructs
tissue-specific local volume transfer constants - synthetic DCE-MRI experiments: (a) synthesis of image series; (b) scatter simplex of
synthesized image series; (c) tissue-specific compartmental tracer concentration curves and local volume transfer constant maps,
estimated by MTCM; (d) MDL model selection to detect the number of compartments; (e) tissue-specific compartmental tracer
concentration curves estimated by principle component analysis (PCA).
doi:10.1371/journal.pone.0112143.g002
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dynamic PET imaging data [24], acquired from both human
tissue/organ and whole-body mouse model (e.g., Fig. S4).
Theoretically, the MTCM method can produce confident
estimation on any ‘dynamic contrast-enhanced’ imaging data with
sufficient quality (e.g., spatial and temporal resolution) [25,26].
However, we should emphasize that there are a few fundamental
assumptions behind the MTCM methodology, as specified in the
newly proved theorems (e.g., linear convex combination, existence
of pure-tissue pixels). As in most medical imaging analysis, object
motion constitutes a major source of error and can significantly
confound the modeling results. Currently, MTCM is limited to
‘parallel’ compartment models, while the CAM part of the
MTCM algorithm is applicable to resolving partial-volume
contamination problem independent of the compartment models
being used for subsequent parameter estimation.
Methods
Multi-tissue compartment modeling of DCE-MRI series
Let us consider J-tissue compartment model of DCE-MRI series
(the Jth tissue compartment corresponds to tracer plasma input,
indexed by p), whose tracer concentration kinetics are governed by









Cmeasured(t)~C1(t)z   zCJ{1(t)zKpCp(t),
ð1Þ
where Cj(t) is the tracer concentrations in the interstitial space
weighted by the fractional interstitial volume in tissue-type j at
time t for j=1,…, J, where J is the total number of vascular
compartments;Cp(t) is the tracer concentration in plasma (tracer
input function); Cmeasured(t) is the measured tracer concentration;
K transj is the unidirectional volume transfer constant (/min)from
plasma to tissue-type j; kep,j is the flux rate constants (/min) in
tissue-type j; and Kp is the plasma volume[28].
Solving (1) leads to Cj(t)~Cp(t)6 exp ({kep,j t), j~1,:::,J-1,
where :denotes the mathematical convolution, and CJ (t)~Cp(t).
The spatial-temporal patterns of tracer concentrations (pixel time-
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where Cmeasured(i,tl) is the tracer concentration at time tl at pixel i,
L is the number of sampled time points, K trans1 (i),:::,K
trans
J{1 (i) are
the local volume transfer constants of the tissue-types 1 to (J-1), at
pixel i, respectively; and Kp(i) is the local plasma volume at pixel i.
Figure 3. Quantitative estimates of tissue-specific pharmacokinetic parameters in a longitudinal breast cancer study reveal
changes in tumor vascular behavior in response to hybrid anti-angiogenesis chemotherapy. While tumor size regression (largely
determined by bulk tumor populations rather than rarer cancer stem cells) is clearly observed, together with a transient ‘‘normalization’’, the detected
tumor islands of persistent enhancement predict the confirmed recurrence despite the dramatic size changes. (a) Snapshots of DCE-MRI sequences
taken from the same tumor before, during, and after therapy. (b) Scatter simplex of baseline DCE-MRI data taken before therapy; estimated tissue-
specific compartmental time-activity curves; and example images of the associated local volume transfer constants. (c) Scatter simplex of interim
DCE-MRI data taken during therapy; estimated tissue-specific compartmental time-activity curves; and example images of the associated local volume
transfer constants. (d) Scatter simplex of closing DCE-MRI data taken after therapy; estimated tissue-specific compartmental time-activity curves; and
example images of the associated local volume transfer constants.
doi:10.1371/journal.pone.0112143.g003
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Parallelism between multi-tissue compartment modeling
and the theory of convex sets
Apply a sum-based normalization to pixel time-course





K transj (i)Cj , ð3Þ
where K transj (i) is accordingly normalized over j, Cmeasured(i) and
Cj are the vector notations (over time) of pixel time course
Cmeasured(i,tl) and compartment time course Cj(tl), respectively.
Since K transj (i) is always non-negative, as a non-negative linear
combination of CJ~ Cj
 
, the set of pixel time-course
Cmeasured~ Cmeasured(i)f g forms a subset of the convex set readily













MTCM exploits the strong parallelism between the multi-
compartment model (3) and the theory of convex set. The
fundamental principle is that latent compartments are pure
vasculatures in a tumor whose pharmacokinetics Cj
 
reside at
the extremities of the scatter simplex occupied by the pixel time-
courses, and accordingly, the interior of the simplex is occupied by
the partial-volume pixels (linear non-negative mixtures of com-
partments) (Fig. 1b). Estimates of compartment pharmacokinetics
may then be derived from the vertices of the multifaceted simplex
that most tightly encloses the pixel time-courses and has the same
number of compartments as vertices (Fig. 1d) [30]. MTCM
algorithm is supported theoretically by a well-grounded mathe-
matical frameworkas summarised below (see formal proofs in
Appendix S2 in File S1).
Theorem 1 (Convexity of pixel time-course)
Suppose that the J compartment pharmacokinetics Cj
 
are





local volume transfer constants K transj (i)
n o
are non-negative and
have at least one pixel whose signal is highly and exclusively
enriched in a particular vascular compartment, then, Cmeasured






i~1 ai~1g which is in fact identical to the







tices are the J compartment pharmacokinetics Cj
 
.
Theorem 2 (Optimum source dominance)










of the pixel time-course scatter simplex. Then the MTCM solution
based on these vertices Ktrans(vj)
 
achieves the maximum source
dominance in the sense of K transm (vj)~ max
i~1,2,:::N
K transm (i).
From Theorems 1 and 2, there is a mathematical solution
uniquely identifying the compartment model (3) based on the
observed set of pixel time-course Cmeasured~ Cmeasured(i)f g (iden-
tifiability and optimality): The vertices of convex set H Cmeasuredf g
are the J compartment pharmacokinetics Cj
 
when there is at
least one pixel whose signal is highly and exclusively enriched in a
particular vascular compartment(Fig. 1b). This means that, in
principle, under a noise-free scenario, we can directly estimate
Cj
 
by locating the vertices of H Cmeasuredf g (Fig. 1d).
Data preprocessing
First, the tumor area is extracted by masking out the non-tumor
tissues surrounding the tumor site [31] (Fig. 1a). Second, the first
few image frames, such as the four initial images of DCE-MRI
sequences in our experiments, are removed because they
correspond to the time prior to sufficient onsite tracer uptake.
Third, pixels whose temporal average signal intensity is lower than
5% of the maximum value, or whose temporal dynamic variation
is lower than 5% of the maximum value, are eliminated, because
these non-informative pixels could have a negative impact on
subsequent analyses. Fourth, the pixel time series is normalized
over time using a sum-based normalization scheme, focusing the
analysis on the ‘‘shape’’ of pharmacokinetics rather than on
absolute tracer concentration.
It is true that accurate extraction of tumor region is critical to
any image-based analysis that is focused on tumor characteriza-
tion, where non-tumor tissue would constitute a confounding
factor. Theoretically, MTCM method can handle well such
situation since it is a completely unsupervised approach, relying on
the MDL-based model selection. Specifically, since MTCM is
specifically designed to work on multiple tissue compartment
modeling, when a significant portion of the surrounding healthy
tissue is included in the processed ‘tumor’ area, the healthy tissue
will be considered as an additional/individual compartment in Eq.
(1) and Fig. 1c. The MDL-based model selection procedure will
statistically determine the number of underlying tissue compart-
ments in the processed area, e.g., whether the contribution of
surrounding healthy tissues is significant to be considered as an
independent compartment. Though MTCM methodology can
accept the processed area extracted by any image segmentation
methods, the tumor region in our study can be outlined by a
collaborative effort by computer scientists and clinicians (Wang,
Adali et al. 1998, Xuan, Adali et al. 2000, Li, Wang et al. 2001). In
the case of heavy noise and fuzzy boundary, a consensus approach
may be adopted that surveys the results of multiple methods.
Clustering of pixel time-course
To reduce the impact of noise/outlier data points, improve the
efficiency of subsequent convex analysis of mixtures, and permit an
automated determination of the number of underlying vascular
compartments using the minimum description length (MDL)
criterion, we aggregated pixel time-courses into representative
clusters using a combined affinity propagation and expectation-
maximization clustering [32] (Fig. 1b, Appendix S2 in File S1).As
an initialization-free and near-global-optimum clustering method,
affinity propagation clustering (APC) simultaneously considers all
data points as potential exemplars and recursively exchange real-
valued messages between data points until a high-quality set of
exemplars and corresponding clusters gradually emerges. Let the
‘‘similarity’’ s i,mð Þ indicate how well the mth data point is suited to
be the exemplar for ith data point; the ‘‘responsibility’’ r i,mð Þ reflects
the accumulated evidence for how well-suited themth data point is to
serve as the exemplar for the ith data point; the ‘‘availability’’ a i,mð Þ
reflects the accumulated evidence for how appropriate the ith data
point chooses mth data point as its exemplar. Then, supposing that
there areN data points (e.g., pixels) in total, the responsibilities r i,mð Þ
are computed based on
Unsupervised Deconvolution of Intratumor Heterogeneity
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e112143
r i,mð Þ/s i,mð Þ{ max
m0[f1,:::,Ng\ m0=m
a i,m0ð Þzs i,m0ð Þf g, ð5Þ
where the availabilities a i,mð Þ are initialized to zero and the
competitive update rule (5) is purely data-driven. Whereas the
responsibility update (5) allows all candidate exemplars to compete
for ownership of a data point, the availability update rule
a i,mð Þ/min 0,r m,mð Þz
X
i0[f1,:::,Ng, i0=i, i0=m





collects evidence from data points to support a good exemplar, where
the ‘‘self-availability’’ is updated differently a m,mð Þ/X
i0=[m
max 0,r i0,mð Þf g. Then, the availabilities and responsibilities
are combined to identify exemplars m ~ argmax
m
a i,mð Þzf
r(i,m)g. The update rules are repeated iteratively and terminated
when no change occurs for 10 iterations [32].
Convex analysis of mixtures
To identify the vertices of convex set H Cmeasuredf g, we
performed convex analysis of mixtures (CAM) on the obtained
M cluster centers Cmf g (Fig. 1d). We assumed J vascular
compartments and conducted an exhaustive combinatorial search
(with total CMJ combinations), based on a convex-hull-to-data
fitting criterion, to identify the most probable J vertices






















where we have d
m, 1,:::Jf g[CM
J




then selected the most probable J vertices when the corresponding
sum of the margin between the convex hull and the remaining
‘‘exterior’’ cluster centers reaches its minimum:










One important discovery step concerning MTCM is to detect
the number J of the underlying tissue compartments. We used
MDL, a widely-adopted and consistent information theoretic
criterion, to guide model selection (Appendix S2 in File S1). We
performed CAM on several competing candidates, and selected
the optimal model that assigns high probabilities to the observed
data while at the same time whose parameters are not too complex
to encode [33]. Specifically, a model is selected with J tissue
compartments by minimizing the total description code length
defined by





where L :ð Þ denotes the joint likelihood function of the clustered
compartment model, CM denotes the set of M cluster centers, and
H Jð Þ denotes the set of freely adjustable parameters in the
clustered compartment model (see Appendix S2 in File S1).
Estimation of pharmacokinetics parameters in MTCM
Having determined the pure-volume pixels associated with the
vertices of H CJf g and the value of J, we estimated the values of
tissue-specific vascular compartment pharmacokinetics parame-
ters, i.e., flux rate constants kep,j
 
and volume transfer con-
stants K transj
n o
, where the vertex of fastest tracer enhancement
(reaching its peak most rapidly) is identified as Cp (Appendix S2






















subject to K transj w0and kep,jw0
ð10Þ
,for j~1,:::,J{1. Subsequently, we estimated local volume
transfer constants by solving






n o Cmeasured ið Þ{
XJ
j~1
K transj (i)Cj k^ep,j
  
2
subject to K transj ið Þ§0,Vj
ð11Þ
which readily reveals the intratumor vascular heterogeneity.
Synthetic DCE-MRI datasets
We first validated MTCM-generated estimates of tissue-specific
vascular pharmacokinetics parameters using a set of realistic
synthetic DCE-MRI data with known parameter values. We set
J=3, indexing two tissue compartments and one plasma input.
We generated a large number of synthetic DCE-MRI time series
by multiplying the customized local volume transfer constant maps
K transj ið Þ
n o




. Synthetic data were comprised of 50 replicated
datasets generated for each of the 12 parameter settings (Data
S1). We performed MTCM on all the datasets and compared the
estimates of tissue-specific kinetic parameters produced by MTCM
with the ground truth, in terms of both biases (accuracy) and
variance (reproducibility) of the estimates, measured over 50
replicated datasets. For comparison purposes, we also evaluated
the three most relevant methods (Table S1). To determine
whether the proposed MDL criterion detects the correct number
of underlying tissue compartments, we calculated the MDL values
for J~2, 3, :::, 6 and identified the most probable value of J when
MDL achieves its minimum value(s) (Fig. 2).
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Characterization of differential vascular pharmacokinetics
in advanced breast cancer case
In the second application, we analyzed the real DCE-MRI data
of an advanced breast tumor using both MTCM and the classic
method. The T1-weighted gadolinium-enhanced (Gd-DTPA)
DCE-MRI data set was acquired by three-dimensional scans
performed every 30 seconds for a total of 11 minutes after the
injection, on a 1.5 Tesla magnet using three-dimensional spoiled
gradient-echo sequences (TR,7 msec, TE,1.5 msec, flip angle
= 30u, matrix = 1926256, 0.5 averages). Typically, 12–15 slices
are obtained and 15–18 time frames are acquired for each case.
We visually examined the convexity of projected pixel time-course
via the top two convexity-preserved projections where the margin
between the ‘‘exterior’’ data points and the convex hull is
minimized. We observed that two-tissue compartments (a three-
vertex convex set) were sufficient to describe the observed pixel
time-course scatter simplex. While additional compartments can
be used to account for outlier vertices, these compartments
become difficult to interpret. We analyzed the dataset by setting
J~4,5,6 and observed noise-like and biologically implausible
pharmacokinetics patterns. The minimum value of MDL
confirmed J=3. The number of clusters M takes values between
12 and 18, determined automatically by the APC algorithm.
Characterizing longitudinal changes of differential
vascular pharmacokinetics in treating angiogenic-active
breast cancer case
Vascular pharmacokinetics parameter values estimated by
MTCM reveal longitudinal changes that may serve as the
evidence of differential and heterogeneous responses to therapy.
We analyzed the data sets arising from a longitudinal study of
tumor response to anti-angiogenic therapy using similar imaging
protocols (Data S3). Three sets of DCE-MRI data were acquired
during standard treatment, each three months apart, serving as the
potential endpoints in assessing the response to therapy. To detect
various yet potentially hidden changes accounting for intratumor
heterogeneity, we applied the same MTCM and MDL (as well as
the classic method) to the three data sets separately.
Open source multiplatform standalone MTCM Java-R
software
Java GUI supported MTCM was implemented in both R and
MATLAB, and runs on both Microsoft Windows and Linux
platforms (http://mloss.org/software/view/437/). MTCM takes
input the.mat data files that record the pixel time-course of DCE-
MRI data in matrices. Each row corresponds to a time frame and
each column corresponds to a pixel. Results of MTCM are
provided to the users via a Java-based GUI (Fig. S5).
Supporting Information
Figure S1 MTCM estimates time-activity curves in
multiple vascular compartments simultaneously and
quantitatively reconstructs tissue-specific local volume
transfer constants – mouse DCE-MRI experimental
data. (a) Snapshots of DCE-MRI sequence taken from the same
tumor at 26 time points. Time point 1 is pre-contrast, and time
points 2-26 are post-contrast. The first two time points are
removed in the experiment. Each time point contains 4 sections
from the same tumor. (b) The MDL curve of model selection and
3 is the optimal choice corresponding to the minimum MDL
value. (c) Estimated tissue-specific compartmental time-activity
curves: ‘blue’ - plasma input function; ‘red’ – fast flow kinetics;
‘green’ – slow flow kinetics. (d) Estimated maps of local volume
transfer constants from four sections in the same tumor.
(TIFF)
Figure S2 Comparison of time-activity curves of total
vascular pool within the region of interests and tissue-
specific time-activity curves estimated by MTCM, in a
longitudinal DCE-MRI study on a breast cancer tumor:
(a) – (c) time-activity curves of total vascular pool; (d) –
(f) MTCM-estimated time-activity curves of fast flow
pool; (g) – (i) MTCM-estimated time-activity curves of
slow flow pool; (j) – (l) MTCM-estimated time-activity
curves of plasma input function.
(TIFF)
Figure S3 MTCM dissects tissue compartments into
anatomical structures of the mouse using dynamic
fluorescence molecular imaging data acquired on a
mouse after bolus injection of indocyanine green dye,
allowing the longitudinal identification of the internal
organs. (a) Physiologically interpretable biodistribution dynamics
of the major organs with ten fluorescence time courses showing
distinct patterns of circulating, accumulating, or metabolizing the
dye in different organs. (b) The merged and color-coded maps of
the dissected tissue compartments agree well with a digital
anatomical mouse atlas. (c) The gray-scale maps of the dissected
individual tissue compartment (Kidney: Ktrans = 1.0004,
kep = 0.0134; Spine: K
trans = 1.0269, kep = 0.0241; Antipose:
Ktrans = 0.7333, kep = 0.0100; Large intestine: K
trans = 0.7808,
kep = 0.0203; Nodes: K
trans = 0.6719, kep = 0.0049; Blood vessels:
Ktrans = 0.9891, kep = 0.0222; Liver: K
trans = 0.7839, kep = 0.0128;
Brain: Ktrans = 0.7553, kep = 0.0258; Stomach: K
trans = 0.8955,
kep = 0.0143; Lung: K
trans = 0.6656, kep = 0.0167).
(TIFF)
Figure S4 MTCM estimates time-activity curves in
multiple DCE-MRI data produced in clinical practice.
(a) – (c) show raw image series, scatter simplex of image series and
estimated tissue-specific compartmental time-activity curves and
local volume transfer constant maps, respectively for a case; (d) – (f)
display the same things for another case.
(TIFF)
Figure S5 MTCM software package in R and Java is
developed to implement MTCM algorithm, as well as
the other algorithms widely used in blind source
separation. The user-friendly Java GUI (a) can generate the
tissue-specific local volume transfer constants and pharmacokinetic
parameters on the right. Two pop-up windows (b) will show the
projection of clustered pixels on the simplex, and (c) will display
the estimated tissue-specific compartmental time-activity curves.
(TIFF)
Table S1 Comparison of tissue-specific kinetic param-
eter estimation by MTCM and three most relevant
methods, based on synthetic DCE-MRI experimental
data.
(DOCX)
Table S2 Tissue-specific kinetic parameter estimates
by MTCM on mouse DCE-MRI experimental data.
(DOCX)
Table S3 MTCM estimates of flux rate constants and
volume transfer constants of a breast cancer tumor
before, during, and after treatment in the longitudinal
study.
(DOCX)
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Table S4 Fractions of partial-volume pixels before,
during, and after treatment in the longitudinal study.
(DOCX)
Table S5 MTCM estimated tissue heterogeneity score
before, during, and after treatment in the longitudinal
study.
(DOCX)
Data S1 Synthetic datasets generated for 12 parameter
settings.
(PDF)
Data S2 DCE-MRI data sets arising from mouse DCE-
MRI experiments.
(PDF)
Data S3 DCE-MRI data sets arising from a longitudinal
study of tumor response to anti-angiogenic therapy.
(PDF)
File S1 Supplementary discussion (appendix S1) and
supplementary method (appendix S2).
(DOCX)
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